These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 30478013)

  • 1. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomics in RCC.
    Syed JS; Brito J; Pooli A; Boutros PC; Shuch B
    Urol Oncol; 2020 Oct; 38(10):742-754. PubMed ID: 32222350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy in renal cell carcinoma.
    Gul A; Rini BI
    Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
    Gurram S; Al Harthy M; Ball MW
    Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascularity as a prognostic marker in renal cell carcinoma.
    Bauman TM; Huang W; Lee MH; Abel EJ
    Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
    Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
    Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
    Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
    Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.
    Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C
    Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809
    [No Abstract]   [Full Text] [Related]  

  • 14. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
    Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
    García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
    BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomics of renal cell carcinoma and its role in renal mass biopsy.
    Salami SS; George AK; Udager AM
    Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling in renal cell carcinoma.
    Dizman N; Philip EJ; Pal SK
    Nat Rev Nephrol; 2020 Aug; 16(8):435-451. PubMed ID: 32561872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.